Biodesix (NASDAQ:BDSX) Releases Earnings Results, Beats Estimates By $0.32 EPS

Biodesix (NASDAQ:BDSX) issued its quarterly earnings data on Monday. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.32, Zacks reports. The company had revenue of $25.56 million during the quarter, compared to analyst estimates of $23.12 million. Biodesix had a negative return on equity of 1,760.83% and a negative net margin of 33.26%.

Here are the key takeaways from Biodesix’s conference call:

• Biodesix reported first-quarter revenue of $25.6 million (up 42% YoY) and raised 2026 guidance to $108–$114 million, implying ~25% growth at the midpoint versus 2025.
• Gross margin expanded to 84% GAAP (82% ex one‑time benefit), adjusted EBITDA loss improved 35% to a $4.1 million loss and net loss narrowed 30%, signaling continued operating leverage and progress toward sustained profitability.
• Diagnostic momentum includes ~17,800 tests in Q1 (up 29% YoY) with primary care now ~15% of volumes and a field team of ~100 reps (adding ~6 reps/quarter); management expects volume-driven growth but is reinvesting in commercial capacity, which raises near‑term operating expense.
• Development services revenue nearly doubled to $3.3 million and the company exited the quarter with about $10.4 million in contracted backlog, reflecting sustained biopharma demand and multi‑omic differentiation.

Biodesix Trading Up 32.6%

NASDAQ BDSX opened at $14.94 on Wednesday. Biodesix has a 12 month low of $3.44 and a 12 month high of $20.21. The stock has a market cap of $151.04 million, a PE ratio of -3.68 and a beta of 0.43. The stock’s 50 day moving average is $14.43 and its 200 day moving average is $10.41.

Wall Street Analyst Weigh In

BDSX has been the subject of several research reports. Canaccord Genuity Group increased their price objective on shares of Biodesix from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday. William Blair upgraded shares of Biodesix from a “market perform” rating to an “outperform” rating in a research report on Friday, February 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Biodesix in a report on Monday. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Biodesix presently has an average rating of “Moderate Buy” and an average target price of $33.00.

Insider Transactions at Biodesix

In related news, CEO Scott Hutton sold 3,559 shares of the firm’s stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $10.08, for a total transaction of $35,874.72. Following the completion of the transaction, the chief executive officer directly owned 45,413 shares of the company’s stock, valued at approximately $457,763.04. This trade represents a 7.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have sold 9,052 shares of company stock worth $100,227. Company insiders own 23.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd lifted its position in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after buying an additional 102,494 shares in the last quarter. DRW Securities LLC bought a new position in Biodesix during the fourth quarter valued at approximately $105,000. Trexquant Investment LP purchased a new position in Biodesix during the 4th quarter valued at approximately $187,000. Geode Capital Management LLC increased its stake in Biodesix by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock worth $289,000 after acquiring an additional 2,235 shares during the last quarter. Finally, State Street Corp increased its stake in Biodesix by 15.6% in the 4th quarter. State Street Corp now owns 17,802 shares of the company’s stock worth $121,000 after acquiring an additional 2,400 shares during the last quarter. Institutional investors own 20.96% of the company’s stock.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.